December 8, 2017December 8, 2017

Phase 2 Trial Testing Gazyva Combo Regimens in Relapsed Follicular Lymphoma Now Enrolling Participants

News

Biopharmaceutical company TG Therapeutics and the National Cancer Institute’s SWOG have initiated a Phase 2 trial testing three Gazyva (obinutuzumab) regimens in patients with relapsed or refractory follicular lymphoma. The ... Read more

January 26, 2017

National Cancer Institute Recruiting Patients with Rare Cancers for Immunotherapy Trial

News

The National Cancer Institute (NCI) is conducting the first federally funded immunotherapy trial devoted to rare cancers. Such cancers occur in only six of 100,000 people per year. Anyone in this category ... Read more